An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Sponsors Dendreon Corporation
- 01 Jun 2017 Status changed from completed to discontinued.
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
- 06 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.